“23. SYSTEMATIC REVIEW OF THE COST - EFFECTIVENESS OF PEMBROLIZUMAB IN RECURRENT OR METASTATIC CERVICAL CANCER”, YHCĐ, vol. 66, no. CĐ8-NCKH, Aug. 2025, doi: 10.52163/yhc.v66iCD8.2569.